###begin article-title 0
###xml 119 125 <span type="species:ncbi:9606">Humans</span>
###xml 130 134 <span type="species:ncbi:10090">Mice</span>
Immunoproteasome Overexpression Underlies the Pathogenesis of Thyroid Oncocytes and Primary Hypothyroidism: Studies in Humans and Mice
###end article-title 0
###begin p 1
Conceived and designed the experiments: HJK NRR PC. Performed the experiments: HJK CYC SCT RR MALS KS MK. Analyzed the data: HJK PC. Contributed reagents/materials/analysis tools: HJK CYC SCT RR MALS KS MK PC. Wrote the paper: HJK PC.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Oncocytes of the thyroid gland (Hurthle cells) are found in tumors and autoimmune diseases. They have a unique appearance characterized by abundant granular eosinophilic cytoplasm and hyperchromatic nucleus. Their pathogenesis has remained, thus far, unknown.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 6 21 <span type="species:ncbi:10090">transgenic mice</span>
###xml 146 151 <span type="species:ncbi:9606">human</span>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
Using transgenic mice chronically expressing IFNgamma in thyroid gland, we showed changes in the thyroid follicular epithelium reminiscent of the human oncocyte. Transcriptome analysis comparing transgenic to wild type thyrocytes revealed increased levels of immunoproteasome subunits like LMP2 in transgenics, suggesting an important role of the immunoproteasome in oncocyte pathogenesis. Pharmacologic blockade of the proteasome, in fact, ameliorated the oncocytic phenotype. Genetic deletion of LMP2 subunit prevented the development of the oncocytic phenotype and primary hypothyroidism. LMP2 was also found expressed in oncocytes from patients with Hashimoto thyroiditis and Hurthle cell tumors.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
In summary, we report that oncocytes are the result of an increased immunoproteasome expression secondary to a chronic inflammatory milieu, and suggest LMP2 as a novel therapeutic target for the treatment of oncocytic lesions and autoimmune hypothyroidism.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 140 143 140 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Cooper1">[1]</xref>
###xml 460 463 460 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Caturegli1">[2]</xref>
###xml 465 468 465 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Tallini1">[3]</xref>
###xml 858 861 858 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Montone1">[4]</xref>
Oncocytes and lymphocytic infiltration are the pathologic hallmarks of Hashimoto thyroiditis, one of the most prevalent autoimmune diseases [1]. Thyroid oncocytes, also known as Hurthle cells, Askanazy cells, or oxyphilic cells, derive from the thyroid follicular cell and are characterized by an abundant, eosinophilic and granular cytoplasm (the consequence of an increased number of mitochondria) and a large, hyperchromatic nucleus with prominent nucleoli [2], [3]. Thyroid oncocytes are found not only in Hashimoto thyroiditis but also in long-standing Graves disease, multinodular goiter, benign thyroid neoplasms (Hurthle cell adenoma and granular cell tumor), and malignant thyroid neoplasms (Hurthle cell carcinoma, oncocytic variant of papillary carcinoma, Warthin-like variant of papillary carcinoma, and tall cell variant of papillary carcinoma) [4]. Oncocytes, however, are not limited to the thyroid gland. They are also found in other organs like kidneys and salivary glands.
###end p 9
###begin p 10
###xml 239 242 235 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Caturegli2">[5]</xref>
###xml 244 247 240 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Kimura1">[6]</xref>
###xml 523 526 519 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Caturegli2">[5]</xref>
###xml 91 96 <span type="species:ncbi:10090">mouse</span>
###xml 255 259 <span type="species:ncbi:10090">mice</span>
###xml 484 499 <span type="species:ncbi:10090">transgenic mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 570 585 <span type="species:ncbi:10090">transgenic mice</span>
###xml 629 634 <span type="species:ncbi:9606">human</span>
The pathogenesis of oncocytes has remained overall unknown. We have previously developed a mouse model of Hashimoto thyroiditis based on the chronic production of interferon-gamma (IFNgamma) by the thyroid follicular cell via transgenesis [5], [6]. These mice develop primary hypothyroidism as the direct consequence of a chronic, cytokine-mediated, inhibition of thyroid function, a phenotype that is present also in the absence of infiltrating lymphocytes (obtained by crossing the transgenic mice to RAG deficient mice) [5]. Interestingly, the thyrocytes of IFNgamma transgenic mice assume a morphology resembling that of the human oncocyte.
###end p 10
###begin p 11
###xml 269 272 269 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Tanaka1">[7]</xref>
###xml 408 411 408 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Kloetzel1">[8]</xref>
This paper highlights the role of the immunoproteasome in the pathogenesis of thyroid oncocytes and hypothyroidism. The proteasome is a large barrel-shaped, proteolytic complex present in the nucleus and cytoplasm of all cells to degrade proteins marked with ubiquitin [7]. It is implicated in a number of fundamental cellular activities such as the processing of antigens presented by MHC class I molecules [8]. The constitutive proteasome is made of a 20S catalytic core closed at both ends by a 19S cap. The core is formed by four stacked rings, each made of seven subunits: two alpha rings are on the sides and allow the entrance of only denatured proteins; two beta rings are in the center and perform the protease activity, reducing proteins to small peptides of 3-23 amino acids. Proteolysis is carried out by three beta subunits, beta1, beta2, and beta5, which harbor postglutamyl peptide hydrolytic-like, trypsin-like, and chymotrypsin-like activities, respectively. When the cell is stimulated by IFNgamma or other inflammatory stimulants like tumor necrosis factor alpha, three subunits in the beta rings and two in the cap are replaced by new subunits called ibeta1 (or LMP2), ibeta2 (or LMP10), ibeta5 (or LMP7), PA28alpha and PA28beta, overall giving to the complex the name of "immunoproteasome". The ibeta1 and ibeta2 subunits must be assembled together, and similarly PA28alpha and PA28beta, but variations in immunoproteasome do exist. The genes coding for LMP subunits are embedded within the class II region of the MHC locus on chromosome 6, and are therefore in strong linkage disequilibrium with the classical MHC class II molecules (DP, DR, DQ) that have been associated with numerous autoimmune diseases. In this paper we show that LMP2 is required for the pathogenesis of thyroid oncocytes and hypothyroidism.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Expression of IFNgamma in the Thyroid Transforms Normal Thyrocytes into Oncocytes
###end title 13
###begin p 14
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 88 97 84 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g001">Figure 1A</xref>
###xml 151 160 147 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g001">Figure 1A</xref>
###xml 269 290 265 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g001">Figure 1A, left panel</xref>
###xml 451 473 447 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g001">Figure 1A, right panel</xref>
###xml 630 639 626 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g001">Figure 1B</xref>
###xml 695 699 691 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 726 735 718 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g001">Figure 1C</xref>
###xml 32 47 <span type="species:ncbi:10090">transgenic mice</span>
###xml 414 422 <span type="species:ncbi:9606">patients</span>
###xml 709 724 <span type="species:ncbi:10090">transgenic mice</span>
The thyrocytes of thyr-IFNgamma transgenic mice crowded along a scanty colloidal space (Figure 1A, middle panel), assuming a tall and polygonal shape (Figure 1A, middle panel inset). Their cytoplasm was granular and more eosinophilic than that of wild type thyrocytes (Figure 1A, left panel), and the nucleus enlarged with a prominent nucleolus, resembling the appearance of the oncocytes (Hurthle cells) found in patients with Hashimoto thyroiditis (Figure 1A, right panel). These cellular features were confirmed by electron microscopy, which also revealed an increased number and size of mitochondria in transgenic thyrocytes (Figure 1B). Apoptosis of thyrocytes was not detected by TUNEL in thyr-IFNgamma transgenic mice (Figure 1C).
###end p 14
###begin title 15
Thyroid histopathology.
###end title 15
###begin p 16
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 243 247 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 497 501 489 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 756 760 744 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 32 47 <span type="species:ncbi:10090">transgenic mice</span>
###xml 257 272 <span type="species:ncbi:10090">transgenic mice</span>
###xml 282 287 <span type="species:ncbi:9606">human</span>
###xml 419 426 <span type="species:ncbi:9606">patient</span>
(A) Thyroids from thyr-IFNgamma transgenic mice (middle panel) show a disrupted architecture, with scanty colloid and thickened thyrocytes (inset), an appearance markedly different from that of wild type thyroids (left panel). Thyrocytes from thyr-IFNgamma transgenic mice resemble human Hurthle cells, with eosinophilic and granular cytoplasm and hyperchromatic nucleus, mimicking the features of Hurthle cells from a patient with Hashimoto thyroiditis (right panel). (B) By electron microscopy, thyr-IFNgamma transgenic thyrocytes appear taller (upper right panel) than wild type thyrocytes (upper left panel), and contain more mitochondria (lower right panel, arrow) than wild type (lower left panel). (C) No apoptosis was detected by TUNEL staining in thyr-IFNgamma transgenic thyrocytes.
###end p 16
###begin title 17
Immunoproteasome Subunits Are Highly Expressed in Oncocyte-Like IFNgamma Transgenic Thyrocytes
###end title 17
###begin p 18
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 492 500 488 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s005">Table S1</xref>
###xml 519 527 515 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s006">Table S2</xref>
###xml 611 619 607 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s007">Table S3</xref>
###xml 641 649 637 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s008">Table S4</xref>
###xml 690 694 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 741 748 733 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007857-t001">Table 1</xref>
###xml 946 953 938 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007857-t001">Table 1</xref>
###xml 1163 1172 1148 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g002">Figure 2A</xref>
###xml 1284 1304 1269 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Material and methods</xref>
To characterize at the molecular level the pathologic changes seen in thyr-IFNgamma transgenic thyrocytes, we used long serial analysis of gene expression (Long SAGE) and compared gene expression in transgenic and wild type isolated thyrocytes. A total of 43,718 and 43,908 tags were collected from the transgenic and wild type thyroid libraries, respectively. Major histocompatibility complex (MHC) genes were the most highly expressed genes in transgenic thyrocytes (rank 1, 5, 8 and 10 in Table S1 and 1, 2 and 3 in Table S2), whereas thyroglobulin dominated in wild type controls (rank 1, 2, 6, 7, and 9 in Table S3 and 1, 2, 5 and 7 in Table S4). Comparison of expression tags between thyr-IFNgamma transgenic and wild type thyrocytes (Table 1) revealed that, following the MHC genes, immunoproteasome subunits were most abundantly expressed in transgenics. In particular, the beta subunit type 8 (also known as LMP7) was increased 36 fold (Table 1); then, the remaining four immunoproteasome subunits were increased as follows: 14 fold for PA28beta, 10 fold for beta subunit type 9 (LMP2), 6 fold for PA28alpha, and 5 fold for beta subunit type 10 (LMP10) (Figure 2A). The complete list of expressed tags in the two thyroid libraries can be downloaded from the GEO website (see Material and methods).
###end p 18
###begin title 19
Thyroid expression of immunoproteasome subunits.
###end title 19
###begin p 20
(A) Immunoproteasome SAGE tag numbers, comparing thyr-IFNgamma transgenic to wild type thyrocytes. (B) Immunoproteasome mRNA levels by semi-quantitative RT-PCR, comparing thyr-IFNgamma transgenic to wild type thyrocytes. G3PDH is used as housekeeping control. (C) Immunoproteasome protein expression by immunohistochemistry: all subunits are increased in thyr-IFNgamma transgenic thyroids when compared to wild type thyroids (inset).
###end p 20
###begin title 21
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
Comparison of gene expression by SAGE in thyrocytes isolated from thyr-IFNgamma transgenic (TG) or wild type (WT) mice (shows the genes that displayed the highest TG over WT ratio).
###end title 21
###begin p 22
###xml 235 244 231 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g002">Figure 2B</xref>
###xml 383 392 368 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g002">Figure 2C</xref>
###xml 524 529 505 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr-</italic>
###xml 590 600 567 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s001">Figure S1A</xref>
###xml 684 694 657 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s001">Figure S1B</xref>
###xml 538 553 <span type="species:ncbi:10090">transgenic mice</span>
###xml 570 574 <span type="species:ncbi:10090">mice</span>
###xml 645 648 <span type="species:ncbi:10116">rat</span>
Long SAGE results were confirmed by reverse transcriptase PCR and immunohistochemistry. The mRNA levels of all five immunoproteasome subunits were significantly over-represented in IFNgamma transgenic compared to wild type thyrocytes (Figure 2B). Similarly, the protein levels of LMP2, LMP7, LMP10, PA28alpha and PA28beta were more abundant in IFNgamma transgenics than in controls (Figure 2C). The increased expression of immunoproteasome subunits was directly dependent upon IFNgamma signaling because it disappeared when thyr-IFNgamma transgenic mice were crossed to mice lacking Stat1 (Figure S1A) and could be reproduced in cultured Fisher rat thyroid cells exposed to IFNgamma (Figure S1B). Based on these findings we hypothesize that the oncocytic phenotype is a consequence of increased immunoproteasome expression, secondary to chronic IFNgamma stimulation in our system.
###end p 22
###begin title 23
Pharmacologic Inhibition of the Proteasome Ameliorates the Oncocytic Phenotype
###end title 23
###begin p 24
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 309 312 305 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Adams1">[9]</xref>
###xml 581 590 577 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g003">Figure 3A</xref>
###xml 782 786 778 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 813 822 805 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>
###xml 918 927 910 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>
###xml 976 985 968 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g003">Figure 3C</xref>
###xml 1068 1077 1060 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>
###xml 1130 1139 1122 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>
###xml 1237 1246 1229 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>
###xml 1290 1299 1282 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>
###xml 114 129 <span type="species:ncbi:10090">transgenic mice</span>
###xml 314 318 <span type="species:ncbi:10090">Mice</span>
###xml 469 474 <span type="species:ncbi:10090">mouse</span>
###xml 796 811 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1030 1035 <span type="species:ncbi:10090">mouse</span>
###xml 1092 1097 <span type="species:ncbi:10090">mouse</span>
###xml 1196 1200 <span type="species:ncbi:10090">mice</span>
To assess pharmacologically whether proteasome inhibition influenced the thyroid disease typical of thyr-IFNgamma transgenic mice, we used MLN-273, a compound manufactured by Millennium Pharmaceuticals, Inc. (Cambridge, MA) similar to Velcade, with a inhibitory activity against purified proteasome of 0.2 nM [9]. Mice (N = 114:58 wild type and 56 transgenics) were first treated with increasing doses of formulated MLN-273 (0, 0.1, 0.2, 0.3, 0.4, and 0.5 mg per Kg of mouse weight), following an administration cycle of two injections per week for two weeks and one week of rest (Figure 3A). Injections were begun during the first week of life (typically on day 3), and ranged from a minimum of 4 to a maximum of 24 (1 to 6 cycles). MLN-273 ameliorated the oncocytic morphology in thyr-IFNgamma transgenic mice (Figure 3B, open circles), starting at cumulative doses of 3.6 mg/Kg and reaching a maximum at 6.0 mg/Kg (Figure 3B). An example of improved morphology is shown in Figure 3C, which compares the thyroid appearance of a mouse receiving 6 mg (closed arrow in Figure 3B) to that of a mouse receiving 1.2 mg (open arrow in Figure 3B). No effect on thyroid morphology was seen in wild type mice receiving various doses of MLN-273 (Figure 3B, closed circles), or the mannitol control (Figure 3B, open circles at 0 mg/Kg). Serum T4 levels did not significantly improve upon MLN-273 treatment (data not shown).
###end p 24
###begin title 25
Pharmacologic inhibition of proteasome using MLN-273.
###end title 25
###begin p 26
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 291 295 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 460 464 452 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 539 548 527 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g002">Figure 2B</xref>
###xml 702 706 690 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 93 108 <span type="species:ncbi:10090">transgenic mice</span>
###xml 485 490 <span type="species:ncbi:10090">mouse</span>
###xml 716 731 <span type="species:ncbi:10090">transgenic mice</span>
(A) Schedule of MLN-273 administration. (B) The oncocytic phenotype typical of thyr-IFNgamma transgenic mice (open circles) improved upon MLN-273 administration in a dose-dependent fashion, beginning at cumulative doses of 3.6 mg/Kg of body weight. No morphological changes were observed in thyr-IFNgamma transgenic treated with mannitol control (open circles, dose 0), or in wild type littermates (closed circles). (C) Thyroid morphology at 40X and 100X of a thyr-IFNgamma transgenic mouse treated with 4.8 mg/Kg MLN-273 (closed arrow in Figure 2B), and another treated with 1.2 mg/Kg MLN-273. (D) Administration of 12 injections of 0.3 mg/Kg MLN-273 significantly improved the oncocytic phenotype of thyr-IFNgamma transgenic mice. (E) The improvement was also evident macroscopically by a decrease in goiter size.
###end p 26
###begin p 27
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 269 278 265 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g003">Figure 3D</xref>
###xml 402 411 398 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g003">Figure 3E</xref>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 197 212 <span type="species:ncbi:10090">transgenic mice</span>
We repeated the experiment using a dose of 0.3 mg/Kg for 12 injections (cumulative dose of 3.6 mg/Kg) in 44 mice (28 wild type and 16 transgenic). The oncocytic phenotype improved in thyr-IFNgamma transgenic mice receiving MLN-273 compared to those receiving mannitol (Figure 3D, p = 0.022). The improvement was also evident by an approximate 6-fold reduction in the weight of thyroid-tracheal blocks (Figure 3E).
###end p 27
###begin title 28
Genetic Deletion of LMP2, but Not LMP7, Corrects the Oncocytic Phenotype
###end title 28
###begin p 29
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 142 146 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thyr</italic>
###xml 279 307 271 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g004">Figure 4A left panel, and 4B</xref>
###xml 345 354 337 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g004">Figure 4A</xref>
###xml 437 446 429 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g004">Figure 4A</xref>
###xml 496 500 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 551 572 539 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g004">Figure 4A right panel</xref>
###xml 625 629 613 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 773 777 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 818 827 798 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g004">Figure 4A</xref>
###xml 1106 1116 1082 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s002">Figure S2A</xref>
###xml 1295 1299 1271 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 1326 1336 1298 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s002">Figure S2B</xref>
###xml 89 104 <span type="species:ncbi:10090">transgenic mice</span>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 510 525 <span type="species:ncbi:10090">transgenic mice</span>
###xml 639 654 <span type="species:ncbi:10090">transgenic mice</span>
###xml 812 816 <span type="species:ncbi:10090">mice</span>
###xml 1027 1031 <span type="species:ncbi:10090">mice</span>
###xml 1309 1324 <span type="species:ncbi:10090">transgenic mice</span>
To assess genetically the effects of immunoproteasome blockade, we crossed thyr-IFNgamma transgenic mice to mice lacking either LMP2 or LMP7. Thyr-IFNgamma transgenic - LMP2 knockout mice showed a significantly improved thyroid morphology, with minimal architectural disruption (Figure 4A left panel, and 4B), and a limited number of oncocytes (Figure 4A middle panel, and 4C). Their thyrocytes resembled those of wild type littermates (Figure 4A middle panel). The phenotype was intermediate in thyr-IFNgamma transgenic mice having one copy of LMP2 (Figure 4A right panel). The scattered mononuclear infiltration typical of thyr-IFNgamma transgenic mice, instead, was not affected by the absence of LMP2, and lymphocytes could still be seen in the thyroid interstitium of thyr-IFNgamma transgenic-LMP2 knockout mice (Figure 4A middle panel). Overall, these results suggest that LMP2 is directly involved in the formation of oncocyte initiated by IFNgamma. During these studies we also noted that thyroid follicular cells from mice lacking only LMP2 were flatter than those observed in wild type controls (Figure S2A), suggesting an effect of LMP2 on thyroid hormonogenesis. In contrast to LMP2, lack of LMP7 did not improve the disrupted thyroidal morphology or the oncocytic phenotype seen in thyr-IFNgamma transgenic mice (Figure S2B).
###end p 29
###begin title 30
Genetic deletion of LMP2 ameliorates thyroid morphology and function.
###end title 30
###begin p 31
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 160 164 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 435 439 427 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 604 608 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
###xml 198 203 <span type="species:ncbi:10090">mouse</span>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
###xml 618 633 <span type="species:ncbi:10090">transgenic mice</span>
(A) Thyroid architecture of a thyr-IFNgamma transgenic-LMP2 knockout mouse at 40X (left panel) and 160X magnification (middle panel). Thyroid architecture of a thyr-IFNgamma transgenic-heterozygous mouse (right panel). (B) Disruption score of the thyroid gland architecture in the 6 genotypes. (C) Oncocytic score in the 6 genotypes. (D) Serum total T4 levels in the 6 genotypes: lack of LMP2 ameliorates the hypothyroidism typical of thyr-IFNgamma transgenics. (E) Body weight of male (left panel) and female (right panel) mice in the 6 genotypes: lack of LMP2 ameliorates growth retardation typical of thyr-IFNgamma transgenic mice.
###end p 31
###begin title 32
Genetic Deletion of LMP2 Corrects the Hypothyroidism and Growth Defect Induced by IFNgamma
###end title 32
###begin p 33
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 136 139 132 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Caturegli2">[5]</xref>
###xml 148 151 144 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Kimura1">[6]</xref>
###xml 171 174 167 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Kimura1">[6]</xref>
###xml 217 221 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 280 289 272 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g004">Figure 4D</xref>
###xml 353 373 345 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g004">Figure 4E left panel</xref>
###xml 388 409 380 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g004">Figure 4E right panel</xref>
###xml 453 457 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 507 536 495 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g004">Figure 4A right panel, and 4B</xref>
###xml 781 790 765 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g004">Figure 4D</xref>
###xml 816 825 800 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g004">Figure 4E</xref>
###xml 47 62 <span type="species:ncbi:10090">transgenic mice</span>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
We have previously reported that thyr-IFNgamma transgenic mice develop primary hypothyroidism (low T4, high TSH, and low iodine uptake) [5], goiter [6], and growth defect [6]. When crossed to LMP2 deficient mice, the thyr-IFNgamma double mutant mice corrected the hypothyroidism (Figure 4D, sixth group) and restored a normal body weight in both males (Figure 4E left panel) and females (Figure 4E right panel). These ameliorations were intermediate in thyr-IFNgamma transgenics with a single copy of LMP2 (Figure 4A right panel, and 4B fifth group). The results indicate that LMP2 is involved not only in oncocyte formation but also in the development of hypothyroidism and growth defect initiated by IFNgamma. LMP2 deficiency by itself had no influence on circulating T4 levels (Figure 4D, third group) or growth (Figure 4E, third group).
###end p 33
###begin p 34
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 76 80 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 121 130 113 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s003">Figure S3</xref>
###xml 213 222 205 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s003">Figure S3</xref>
###xml 262 271 254 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s003">Figure S3</xref>
###xml 441 451 433 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s002">Figure S2A</xref>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 238 242 <span type="species:ncbi:10090">Mice</span>
Thyroid accumulation of radioactive iodine in thyr-IFNgamma transgenics and thyr-IFNgamma transgenic-LMP2 knockout mice (Figure S3, third and fourth group) was significantly lower than that of wild type controls (Figure S3, first group). Mice lacking only LMP2 (Figure S3, second group) also had a significantly lower radioiodine accumulation than wild type controls, in keeping with the flattened thyrocyte morphology previously described (Figure S2A). LMP2 thus emerges as an important regulator of thyroid structure and function, capable of modulating iodine accumulation independently of IFNgamma.
###end p 34
###begin title 35
###xml 21 26 <span type="species:ncbi:9606">Human</span>
LMP2 Is Expressed in Human Thyroid Oncocytes (Hurthle Cells)
###end title 35
###begin p 36
###xml 312 319 312 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007857-t002">Table 2</xref>
###xml 515 535 515 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g005">Figure 5, left panel</xref>
###xml 562 582 562 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g005">Figure 5, left panel</xref>
###xml 755 763 755 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g005">Figure 5</xref>
###xml 794 815 794 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g005">Figure 5, right panel</xref>
###xml 906 916 906 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s004">Figure S4A</xref>
###xml 1020 1030 1020 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007857.s004">Figure S4B</xref>
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 855 863 <span type="species:ncbi:9606">patients</span>
Given the key role of LMP2 in the induction of mouse oncocytes, we assessed whether LMP2 was also expressed in archival thyroid glands removed from patients with Hashimoto thyroiditis, Graves disease, Hurthle cell adenoma, or Hurthle cell carcinoma. LMP2 was expressed in all 19 Hashimoto thyroiditis specimens (Table 2) with mention of Hurthle cells and in most of those (5 of 6) where Hurthle cells were not mentioned by the pathologist. LMP2 staining in Hashimoto thyroiditis was diffuse throughout the section (Figure 5, left panel) and of strong intensity (Figure 5, left panel inset), often useful to spot oncocytes in the midst of the diffuse mononuclear cell infiltration typical of this disease. LMP2 was also expressed in Hurthle cell adenomas (Figure 5, middle panel) and carcinoma (Figure 5, right panel), although levels varied greatly among patients and different areas of the same specimen (Figure S4A). LMP7 expression followed that of LMP2 in Hashimoto thyroiditis, Hurthle cell adenoma, and carcinoma (Figure S4B).
###end p 36
###begin title 37
###xml 19 24 <span type="species:ncbi:9606">human</span>
LMP2 expression in human thyroid.
###end title 37
###begin p 38
###xml 39 47 <span type="species:ncbi:9606">patients</span>
LMP2 expression marks Hurthle cells in patients with Hashimoto thyroiditis (left panel) Hurthle cell adenoma (middle panel), or Hurthle cell carcinoma (right panel). The inset on the left panel shows that LMP2 is expressed specifically in Hurthle cells (oncocytes) surrounded by the lymphocytic infiltration.
###end p 38
###begin title 39
Distribution and intensity of LMP2 expression by immunohistochemistry in Hurthle cells present in Hashimoto thyroiditis, Hurthle cell adenoma, Hurthle cell carcinoma, and Graves disease.
###end title 39
###begin p 40
Autoimmune Hurthle cells strongly express LMP2.
###end p 40
###begin p 41
This thyroid pathological specimen contained only infiltrating lymphocytes and no thyroid cells.
###end p 41
###begin p 42
Overall the results suggest that oncocytes (Hurthle cells) arise in response to a chronic inflammatory milieu within the thyroid gland, forming a spectrum of morphological variants, with an "autoimmune Hurthle cell" at one end and a "neoplastic Hurthle cell" at the other end of the spectrum.
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 125 130 <span type="species:ncbi:10090">mouse</span>
###xml 193 198 <span type="species:ncbi:9606">human</span>
The study reports that LMP2, an immunoproteasome subunit, is involved in the generation of oncocytes and hypothyroidism in a mouse model of Hashimoto thyroiditis, and that is also expressed in human oncocyte (Hurthle cell) lesions.
###end p 44
###begin p 45
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Maksymowych1">[10]</xref>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Casp1">[11]</xref>
###xml 341 345 341 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Kramer1">[12]</xref>
###xml 387 391 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Egerer1">[13]</xref>
###xml 415 419 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Scheffler1">[14]</xref>
###xml 535 539 535 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Egerer2">[15]</xref>
###xml 541 545 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Krause1">[16]</xref>
###xml 677 681 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Hayashi1">[17]</xref>
###xml 683 687 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Hayashi2">[18]</xref>
###xml 735 739 735 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Kessler1">[19]</xref>
###xml 741 745 741 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Runnels1">[20]</xref>
###xml 1152 1156 1152 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-VivesPi1">[21]</xref>
###xml 1311 1315 1311 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Griffin1">[22]</xref>
###xml 1383 1387 1383 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Groettrup1">[23]</xref>
###xml 1467 1472 1467 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr-</italic>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
###xml 671 676 <span type="species:ncbi:10090">mouse</span>
###xml 928 936 <span type="species:ncbi:9606">patients</span>
###xml 957 965 <span type="species:ncbi:9606">patients</span>
###xml 1481 1496 <span type="species:ncbi:10090">transgenic mice</span>
The role of LMP2 in the pathogenesis of autoimmune diseases has been explored by a limited number of studies with conflicting results. Some studies have positively linked LMP2 to autoimmunity. For example, polymorphisms in the LMP2 have been associated with autoimmune diseases like ankylosing spondylitis [10], vitiligo [11], and psoriasis [12]. In addition, circulating levels of LMP2 [13] and antibodies to LMP2 [14] are increased in patients with connective tissues disorders like systemic lupus erythematosus and Sjogren syndrome [15], [16]. On the other hand, one group has shown that the lack of splenic LMP2 is linked to development of type 1 diabetes in the NOD mouse [17], [18], a report that has stimulated some controversy [19], [20]. It is likely that the tissue levels of LMP2 change throughout the course of the autoimmune process in a tissue-specific manner. For example, Vives-Pi and colleagues, studying eight patients with Graves disease patients and four with type 1 diabetes, reported that thyroid glands expressed high but variable levels of LMP2 and LMP7, whereas pancreases had levels similar to those found in healthy controls [21]. LMP2 increase did not always correspond to a similar LMP7 increase, in keeping with the notion that these two subunits are not always assembled together [22] in the immunoproteasome, contrary to the pairing of LMP2 and LMP10 [23]. Our finding that only the lack of LMP2, but not LMP7, ameliorated diseases in thyr-IFNgamma transgenic mice supports these observations.
###end p 45
###begin p 46
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 874 882 <span type="species:ncbi:9606">patients</span>
In addition to demonstrating at the molecular and tissue levels that LMP2 is a marker of oncocytes (Hurthle cells) in Hashimoto thyroiditis, this study also reports that LMP2 is increased in thyroid cancer. In patients with Hurthle cell adenomas or carcinomas the expression of LMP2 was clear, although more variable than that observed in Hashimoto thyroiditis. The variability could be due to fine gradations in the oncocytic phenotype: although oncocytes are defined by the combination of morphological features, these features form a continuous spectrum, leading us to hypothesize that the oncocyte emerging in Hashimoto thyroiditis ("autoimmune Hurthle cell) might be different from those found in cancer ("neoplastic Hurthle cell"). This hypothesis remains to be tested. Further studies are also needed to assess whether LMP2 levels correlate with clinical outcomes in patients with Hurthle cell carcinoma.
###end p 46
###begin p 47
###xml 272 276 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Adams2">[24]</xref>
###xml 348 352 344 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Richardson1">[25]</xref>
###xml 385 389 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Fissolo1">[26]</xref>
###xml 405 409 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Neubert1">[27]</xref>
###xml 519 523 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Kuhn1">[28]</xref>
###xml 602 606 595 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Lindenthal1">[29]</xref>
###xml 638 642 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Hu1">[30]</xref>
###xml 780 784 773 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Bonuccelli1">[31]</xref>
###xml 873 877 866 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Chade1">[32]</xref>
###xml 979 983 972 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Fukai1">[33]</xref>
###xml 984 988 977 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Ludwig1">[35]</xref>
###xml 1240 1244 1233 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Kuhn1">[28]</xref>
###xml 101 116 <span type="species:ncbi:10090">transgenic mice</span>
###xml 611 637 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
###xml 737 742 <span type="species:ncbi:10090">mouse</span>
###xml 839 842 <span type="species:ncbi:9823">pig</span>
LMP2 was used in this study as a therapeutic target to control with MLN-273 the oncocytes present in transgenic mice over-expressing IFNgamma in the thyroid gland. MLN-273 (PS-273) is an emerging boronic acid proteasome inhibitor similar to Velcade (bortezomib or PS-341) [24], a drug used in the treatment of several cancers like multiple myeloma [25], and more recently inflammatory [26] and autoimmune [27] diseases. MLN-273, like Velcade, blocks the constitutive proteasome (beta5 subunit) and the immunoproteasome [28]. In vitro, MLN-273 effectively blocks the development of Plasmodium parasites [29] and Mycobacterium tuberculosis [30]. In vivo, MLN-273 halts the degradation of dystrophin and dystrophin-associated proteins in a mouse model of Duchenne muscular dystrophy [31]. It also improves the glomerular filtration rate in a pig model of hypercholesterolemia [32], although there is disagreement on whether targeting the proteasome actually worsens atherosclerosis [33]-[35]. It remains to be tested whether proteasome inhibition is effective in the treatment of Hurthle cell carcinomas. As new inhibitors (like IPSI-001) are being developed that preferentially target the immunoproteasome rather than constitutive proteasome [28], it is possible that this treatment modality will extend to a larger number of autoimmune diseases. The treatment might be also applicable to oncocytic lesions found in other organs, like kidneys, salivary or adrenal glands.
###end p 47
###begin p 48
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr-</italic>
###xml 730 735 726 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thyr-</italic>
###xml 85 100 <span type="species:ncbi:10090">transgenic mice</span>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
###xml 744 759 <span type="species:ncbi:10090">transgenic mice</span>
Interestingly, the lack of LMP2 ameliorated the hypothyroidism seen in thyr-IFNgamma transgenic mice, providing a novel explanation for the pathogenesis of hypothyroidism typically found in patients with autoimmune thyroiditis. Architectural disruption of the thyroid gland by infiltrating lymphocytes and apoptosis of thyrocytes have traditionally been considered the cause of hypothyroidism in autoimmune thyroiditis, but they are not the target of therapeutic interventions, which instead rely on the administration of synthetic thyroxine. Although effective, this symptomatic treatment is unsatisfactory in a discrete percentage of hypothyroid patients, highlighting the need for new treatments based on disease pathogenesis. Thyr-IFNgamma transgenic mice can, therefore, provide a model to study chronic hypothyroidism, a feature not found in most animal models of autoimmune thyroiditis.
###end p 48
###begin p 49
###xml 441 445 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Benvenga1">[36]</xref>
In summary, we report that thyroid oncocytes (Hurthle cells) arise in the thyroid gland in response to a chronic inflammatory milieu concomitant with LMP2 over expression, and suggest they form a spectrum of morphological variants with an "autoimmune Hurthle cell" at one end and a "neoplastic Hurthle cell" at the other end of the spectrum. Considering increasing reports of the association between Hashimoto thyroiditis and thyroid cancer [36], we strongly propose that LMP2 might be a potential therapeutic target for the protective treatment of oncocytic lesions and hypothyroidism as well.
###end p 49
###begin title 50
Materials and Methods
###end title 50
###begin title 51
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 51
###begin p 52
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 356 359 348 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Caturegli2">[5]</xref>
###xml 601 605 577 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 971 975 939 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Nussbaum1">[37]</xref>
###xml 1069 1091 1037 1059 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">: CCCGTGTCCCTCCGAGATAC</named-content>
###xml 1109 1131 1077 1099 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">: GGGATCCAGGACCAGGAAAG</named-content>
###xml 1153 1158 1121 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Psmb9</italic>
###xml 1184 1208 1152 1176 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">: TCTATGGTGGCATCACTATGTT</named-content>
###xml 1225 1249 1193 1217 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">: TGGTACACTGTGGGCGATTGAG</named-content>
###xml 1271 1276 1239 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Psmb8</italic>
###xml 1302 1324 1270 1292 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">: CTTGGGTGGAGAGGCTATTC</named-content>
###xml 1341 1363 1309 1331 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">: AGGTGAGATGACAGGAGATC</named-content>
###xml 1397 1400 1365 1368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neo</italic>
###xml 1549 1553 1517 1521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Durbin1">[38]</xref>
###xml 1648 1674 1616 1642 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">: GAGATAATTCACAAAATCAGAGAG</named-content>
###xml 1693 1714 1661 1682 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">: CTGATCCAGGCAGGCGTTG</named-content>
###xml 1736 1741 1704 1709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat1</italic>
###xml 1781 1807 1749 1775 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">: TAATGTTTCATAGTTGGATATCAT</named-content>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 299 305 <span type="species:ncbi:10090">murine</span>
###xml 615 630 <span type="species:ncbi:10090">transgenic mice</span>
###xml 688 694 <span type="species:ncbi:10090">murine</span>
###xml 730 733 <span type="species:ncbi:10116">rat</span>
###xml 839 843 <span type="species:ncbi:10090">mice</span>
###xml 862 866 <span type="species:ncbi:10090">mice</span>
###xml 1050 1054 <span type="species:ncbi:10090">mice</span>
###xml 1422 1426 <span type="species:ncbi:10090">mice</span>
###xml 1628 1632 <span type="species:ncbi:10090">mice</span>
###xml 1835 1839 <span type="species:ncbi:10090">mice</span>
###xml 2020 2024 <span type="species:ncbi:10090">mice</span>
The study analyzed a total of 366 mice: 216 genetically modified, and 150 C57BL/6 wild type littermate controls. The genetically modified mice included the following genotypes, all on the BL/6 background: thyr-IFNgamma transgenics (N = 95) (a model previously generated in our laboratory to express murine IFNgamma specifically in thyroid follicular cells [5]), LMP2 knockout (N = 29); LMP2 heterozygous (N = 19); LMP2 knockout/IFNgamma transgenic (N = 46); LMP2 heterozygous/IFNgamma transgenic (N = 19); LMP7 knockout/IFNgamma transgenic (N = 5); and STAT1 knockout/IFNgamma transgenic (N = 3). The thyr-IFNgamma transgenic mice were generated as previously described. They express the murine IFNgamma gene under control of the rat thyroglobulin promoter, to support transcription specifically in thyroid follicular cells. LMP2 knockout mice and LMP7 knockout mice (C57BL/6 background) were kindly gifted from Dr. Whitton (The Scripps Research Institute, La Jolla, CA) [37]. The following primers were used for genotyping for LMP2 or LMP7 knockout mice, LMP2-2 primer: CCCGTGTCCCTCCGAGATAC and LMP2-4 primer: GGGATCCAGGACCAGGAAAG to detect endogenous Psmb9 (LMP2) gene, LMP7A primer: TCTATGGTGGCATCACTATGTT and LMP7B primer: TGGTACACTGTGGGCGATTGAG to detect endogenous Psmb8 (LMP7) gene, NEO A primer: CTTGGGTGGAGAGGCTATTC and NEO B primer: AGGTGAGATGACAGGAGATC to detect mutant gene containing neo gene. STAT1 knockout mice, also on the C57BL/6 background, were kindly donated by Dr. David Levy (New York University Medical Center, New York, NY) [38]. The following primers were used for genotyping for LMP2 or LMP7 knockout mice, Stat P1 primer: GAGATAATTCACAAAATCAGAGAG and Stat P2 primer: CTGATCCAGGCAGGCGTTG to detect endogenous Stat1 gene, Stat P1 primer and Stat P3 primer: TAATGTTTCATAGTTGGATATCAT to detect mutant gene. All mice were bred in specific pathogen-free facilities at Johns Hopkins University following protocols conformed to the JHU Animal Care and Use Committee guidelines. For some experiments, mice were weighed at five-week old.
###end p 52
###begin title 53
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Thyroid Glands
###end title 53
###begin p 54
###xml 268 276 <span type="species:ncbi:9606">patients</span>
Thyroid samples (N = 43) for morphological and immunohistochemical studies were obtained from the archival surgical pathology specimens maintained in The Johns Hopkins Pathology Department, using a protocol approved by the Institutional Review Board. Samples included patients with Hashimoto thyroiditis (N = 25), Graves disease (N = 2), Hurthle cell adenoma (N = 9), and Hurthle cell carcinoma (N = 7).
###end p 54
###begin title 55
Histopathology of Thyroid
###end title 55
###begin p 56
###xml 18 23 <span type="species:ncbi:10090">mouse</span>
After euthanasia, mouse tracheas with attached thyroids were removed and fixed for 48 hours in the zinc-based Beckstead's solution or buffer-saturated formalin. The specimen was then processed and embedded in paraffin. Six to 8 non sequential sections (5 microm thick) were cut from the tissue block and stained with hematoxylin and eosin (H&E). The same tissue block used for H&E histopathology was used to cut sections for immunohistochemistry.
###end p 56
###begin title 57
###xml 38 43 <span type="species:ncbi:10090">Mouse</span>
TUNEL Staining to Detect Apoptosis in Mouse Thyroid Glands
###end title 57
###begin p 58
Formalin-fixed thyroid sections were deparaffinized in xylene, rehydrated in decreasing concentrations of ethanol, and washed in phosphate buffer saline (PBS). Sections were then incubated at room temperature in proteinase K (20 microg/ml for 15 min), washed in distilled water, and then incubated in hydrogen peroxide (0.3% for 10 min). TUNEL staining was performed using the ApopTag kit (Chemicon, Temecula, CA). Sections were first equilibrated in the kit buffer and then incubated for 1 hour at 37degreesC in a humidified chamber with terminal deoxynucleotidyl transferase conjugated to digoxigenin. Sections were then placed in a Coplin jar containing working strength stop/wash buffer, agitated for 15 seconds, and incubated for 10 min at RT. After washing in PBS, an anti-digoxigenin antibody conjugated to peroxidase was applied for 30 min at RT. After washing, apoptosis-specific color was obtained using diaminobenzidine, and overall morphology using Eosin Y Alcoholic (Richard-Allan Scientific, Kalamazoo, MI).
###end p 58
###begin title 59
###xml 23 28 <span type="species:ncbi:10090">Mouse</span>
Electron Microscopy of Mouse Thyroid Glands
###end title 59
###begin p 60
###xml 119 120 119 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 266 267 260 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Thyroid glands were fixed for 1 hour at room temperature in 0.1 M cacodylate buffer pH 7.2, supplemented with 3 mM CaCl2, 2% glutaraldehyde, and 4% paraformaldehyde. Glands were then post-fixed for 1 hour at 4degreesC in cacodylate buffer supplemented with 3 mM CaCl2 and 2% osmium tetroxide. Glands were then washed for 30 min in 2% uranyl acetate, and dehydrated first with increasing concentrations of ethanol (50%, 70%, 90% and 100%) and then with propylene oxide. Glands were then infiltrated with a propylene oxide-Epon mixture and embedded flat in Epon. Ultra-thin sections were cut and analyzed for electron microscopy using a Phillips CM12 (S)TEM microscope.
###end p 60
###begin title 61
###xml 64 69 <span type="species:ncbi:10090">Mouse</span>
Long SAGE (Serial Analysis of Gene Expression) of CD45 Negative Mouse Thyrocytes
###end title 61
###begin p 62
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 1311 1316 1285 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1318 1322 1292 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Saha1">[39]</xref>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 552 558 <span type="species:ncbi:9913">bovine</span>
###xml 1118 1124 <span type="species:ncbi:9913">bovine</span>
Thyroid lobes were collected from 3 thyr-IFNgamma transgenic female mice, and 16 wild type female littermates. Lobes were incubated immediately after dissection for 26 hours at 4degreesC in Eagle's minimal essential medium, supplemented with 1.2 U/mL dispase II (Roche Applied Science, Indianapolis, IN) and 0.25 U/mL collagenase II (Sigma, St. Louis, MO), to ensure a thorough diffusion of the enzymes into the tissue. Lobes were then digested for 20 min at 37degreesC in a shaking water bath, and then briefly in cold PBS containing 2 mM EDTA and 1% bovine serum albumin to stop the digestion. After one wash, thyroid cells were first passed through 70 microM mesh filter, to remove large tissue debris, and then incubated for 15 minutes at 4degreesC with anti-CD45 paramagnetic microbeads (Miltenyi Biotech, Auburn, CA). After one wash, the mixture was applied to a MS column (Miltenyi Biotech) in a magnetic separator: the CD45 negative fraction (composed mainly of thyrocytes, parathyroid cells, and endothelial cells) was eluted by the addition of phosphate-buffered saline, supplemented with 2 mM EDTA and 0.5% bovine serum albumin. The magnetic separation was repeated once. CD45 negative thyroid cells were counted with trypan blue and used to extract mRNA and perform Long SAGE as described by Saha S et al. [39]. The SAGE sequencing data are available from the Gene Expression Omnibus repository of the National Center for Biotechnology Information (), using series record number GSE15114.
###end p 62
###begin title 63
###xml 47 52 <span type="species:ncbi:10090">Mouse</span>
Expression of Immunoproteasome Subunit mRNA in Mouse Thyroids by Semi-Quantitative Reverse Transcriptase PCR
###end title 63
###begin p 64
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 316 317 312 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 458 486 450 478 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAAGCCAAGGTGGATGTGTTCC-3&#8242;</named-content>
###xml 505 536 497 528 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene"> 5&#8242;-GATCATTCCCTTGGTTTCTCCACG-3&#8242;</named-content>
###xml 562 588 551 577 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCAGGAGAAGGAAGTCCCTA-3&#8242;</named-content>
###xml 608 637 597 626 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GATGGCTTTTCTTCACCCTTCGG-3&#8242;</named-content>
###xml 659 690 648 679 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ATGCTGCGGGCAGGAGCACCTACCG-3&#8242;</named-content>
###xml 710 742 699 731 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCACTCATCGTAGAATTTTGGCAGCT-3&#8242;</named-content>
###xml 764 796 753 785 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ATGGCGTTACTGGATCTGTGCGGTGC-3&#8242;</named-content>
###xml 816 848 805 837 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCACAGAGCGGCCTCTCCGTACTTGT-3&#8242;</named-content>
###xml 871 899 860 888 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGGAATGCGTCCTTGGAACACG-3&#8242;</named-content>
###xml 919 947 908 936 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCAATGCTCTCTGCAGCTTGGC-3&#8242;</named-content>
###xml 1020 1046 1009 1035 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCATCTTGGGCTACACTGAG-3&#8242;</named-content>
###xml 1070 1096 1059 1085 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCTCTTGCTCAGTGTCCTTG-3&#8242;</named-content>
###xml 363 368 <span type="species:ncbi:10090">mouse</span>
###xml 949 954 <span type="species:ncbi:10090">Mouse</span>
Thyroid lobes from 1-month-old thyr-IFNgamma transgenics (N = 3) and wild type littermates (N = 3) were mechanically homogenized to extract mRNA using oligo (dT)25 magnetic beads (Invitrogen, Carlsbad, CA). Following DNase I (Invitrogen) treatment, mRNA was reverse transcribed into cDNA using Superscript II RNase H- reverse transcriptase (Invitrogen). The five mouse immunoproteasome subunits using the following specific primers: PA28alpha forward primer 5'-CAAGCCAAGGTGGATGTGTTCC-3' and reverse primer 5'-GATCATTCCCTTGGTTTCTCCACG-3', PA28beta forward primer 5'-GCAGGAGAAGGAAGTCCCTA-3' and reverse primer 5'-GATGGCTTTTCTTCACCCTTCGG-3', LMP2 forward primer 5'-ATGCTGCGGGCAGGAGCACCTACCG-3' and reverse primer 5'-TCACTCATCGTAGAATTTTGGCAGCT-3', LMP7 forward primer 5'-ATGGCGTTACTGGATCTGTGCGGTGC-3' and reverse primer 5'-TCACAGAGCGGCCTCTCCGTACTTGT-3', LMP10 forward primer 5'-AGGAATGCGTCCTTGGAACACG-3' and reverse primer 5'-TCAATGCTCTCTGCAGCTTGGC-3'. Mouse G3PDH was amplified as quantitation control using forward primer 5'-GCATCTTGGGCTACACTGAG-3' and the reverse primer 5'-TCTCTTGCTCAGTGTCCTTG-3'. The cDNA from each proteasome sample was sequentially diluted and then amplified for GAPDH. The dilutions that gave similar GAPDH intensities were used for amplification of the proteasome subunits.
###end p 64
###begin title 65
###xml 51 56 <span type="species:ncbi:10090">Mouse</span>
###xml 61 66 <span type="species:ncbi:9606">Human</span>
Expression of Immunoproteasome Subunit Proteins in Mouse and Human Thyroids by Immunohistochemistry
###end title 65
###begin p 66
###xml 449 450 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 451 452 451 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 328 333 <span type="species:ncbi:10090">mouse</span>
###xml 540 544 <span type="species:ncbi:9925">goat</span>
###xml 603 609 <span type="species:ncbi:9986">rabbit</span>
###xml 758 764 <span type="species:ncbi:9913">bovine</span>
###xml 870 875 <span type="species:ncbi:9606">human</span>
###xml 1029 1034 <span type="species:ncbi:10090">mouse</span>
Sections were deparaffinized with xylene, rehydrated with decreasing concentrations of ethyl alcohol and finally PBS. Formalin-fixed sections (human section) were, then, treated with target retrieval solution (DAKO, Carpinteria, CA) for 10 min in steamer; no target retrieval treatment for zinc-based Beckstead's solution-fixed mouse tissues. After cool down and washing with PBS, endogenous peroxidase was blocked by treating the sections with 3% H2O2 in PBS for 30 min at room temperature. After blocking aspecific binding with 5% normal goat serum, sections were incubated with the primary antibody; rabbit anti proteasome subunit (LMP2, LMP7, LMP10, PA28alpha, and PA28beta; Biomol International, L.P., Plymouth Meeting, PA), in PBS supplemented with 1% bovine serum albumin, and incubated overnight at 4degreesC in a humid chamber. Primary antibody was diluted for human thyroid sections as following; LMP2 (1:200), LMP7 (1:2,000), LMP10 (1:1,000), PA28alpha (1:4,000), PA28beta (1:20,000). Primary antibody was diluted for mouse sections as following; LMP2 (1:400), LMP7 (1:10,000), LMP10 (1:4,000), PA28alpha (1:12,000), PA28beta (1:40,000).
###end p 66
###begin p 67
###xml 75 79 <span type="species:ncbi:9925">goat</span>
###xml 85 91 <span type="species:ncbi:9986">rabbit</span>
After washing, the biotin-conjugated secondary antibody (affinity purified goat anti-rabbit IgG, from DAKO, diluted 1:1000 in PBS-1%BSA) was incubated for 1 hr at room temperature. After rinsing, peroxidase-conjugated streptavidin (DAKO) was diluted 1:500 in PBS and incubated for 30 min at RT. Finally, sections were incubated for 5 min with NovaRED substrate or DAB substrate (both from Vector Laboratories, Burlingame, CA) for color development and then rinsed in distilled water. Sections were counter-stained with hematoxylin (Vector Laboratories).
###end p 67
###begin title 68
Proteasome Inhibitor Administration
###end title 68
###begin p 69
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 324 328 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007857-Kuhn1">[28]</xref>
###xml 632 641 625 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007857-g003">Figure 3A</xref>
###xml 73 88 <span type="species:ncbi:10090">transgenic mice</span>
###xml 425 429 <span type="species:ncbi:10090">Mice</span>
To block pharmacologically the function of the proteasome, thyr-IFNgamma transgenic mice and wild type littermates were injected i.p with MLN-273. This compound, a gift from Millennium Pharmaceutical Inc. (Cambridge, MA), blocks like Velcade (Bortezomib) the constitutive proteasome (beta5 subunit) and the immunoproteasome [28]. MLN-273 was formulated as 1 part (8.3%) active compound and 11 parts (91.7%) mannitol vehicle. Mice received MLN-273 or mannitol control twice a week for 2 weeks, then rested for a week, and then were injected again until reaching cumulative formulated doses of 1.2, 2.0, 2.5, 3.6, 4.8, and 6.0 mg/Kg (Figure 3A).
###end p 69
###begin title 70
Assessment of Thyroid Function by Serum Total T4 Levels
###end title 70
###begin p 71
###xml 288 291 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 497 498 493 494 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 575 576 571 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
Serum total thyroxine (T4) was determined by a competitive RIA (Diasorin, Stillwater, MN), according to the manufacturer's instructions. Briefly, ten microl of serum were added to plastic tubes coated with a monoclonal antibody directed against T4. Then, 1 ml of tracer buffer containing 125I-T4 was added to the tubes and the solution incubated at room temperature for 45 min. Tubes were then decanted and counted for 1 min in a gamma counter (Isodata-520, from Titertek, Huntsville, AL). Total T4 concentrations were extrapolated from a standard curve generated using six T4 standards ranging from 0 to 20 microg/dL.
###end p 71
###begin title 72
Radioactive Iodine Uptake (RAIU)
###end title 72
###begin p 73
###xml 194 197 190 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 55 59 <span type="species:ncbi:10090">Mice</span>
###xml 156 160 <span type="species:ncbi:10090">Mice</span>
###xml 243 247 <span type="species:ncbi:10090">Mice</span>
Iodine uptake was determined using radioactive iodine. Mice were fed with iodine-deficient diet (TD95007 from HARLAN TEKLAD, Indianapolis, IN) for 3 weeks. Mice were injected with 10 microCi of 125I (carrier-free, Amersham) intraperitoneally. Mice were sacrificed 4 hours after injection of radioactive iodine, and thyroid lobes and muscle (negative control) were excised, weighed and counted using a gamma counter. Iodine uptake was normalized dividing the count by the weight of each tissue.
###end p 73
###begin title 74
Detection of Thyroidal Gene Expression by Northern Hybridization
###end title 74
###begin p 75
###xml 410 415 <span type="species:ncbi:10090">Mouse</span>
After thyroid lobes were excised and homogenated in TRIZOL (Invitrogen, Carlsbad, CA), total RNA was extracted following manufacture protocol. 10 microg of total RNA was separated by 1% agarose gel electrophoresis and analyzed by Northern blot for the expression of LMP2. The signal from G3PDH was also obtained to adjust for the amount of RNA loaded in each lane; G3PDH probe was synthesized using pTRI-GAPDH-Mouse (Ambion, Austin, TX). Probe signals were quantified using the BAS-1500 Bioimaging Analyzer (Fuji Photo Film Co., Japan).
###end p 75
###begin title 76
Statistical Analysis
###end title 76
###begin p 77
Differences among the six genotypes were assessed using the non-parametric Kruskal-Wallis test, followed by Wilcoxon sing-rank test for the pairwise comparisons. All analyses were performed using Stata statistical software, release 10 (from Stata Corp., College Station, TX).
###end p 77
###begin title 78
Supporting Information
###end title 78
###begin p 79
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 214 218 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 329 332 <span type="species:ncbi:10116">rat</span>
###xml 522 525 <span type="species:ncbi:10116">rat</span>
(A) LMP2 and LMP10 protein expression by immunohistochemistry in thyr-IFNgamma transgenic-STAT1 knockout mice: lack of STAT1 abolishes the expression of both immunoproteasome subunits, as compared to that found in thyr-IFNgamma transgenic-STAT1 wild type controls (insets). (B) LMP2 RNA expression by Northern blotting in Fisher rat thyroid follicular cells (FRTL-5 line) stimulated with IFNgamma. Total RNA was extracted from FRTL-5 cells after 0, 3, 12, 24, 48 or 72 hours of IFNgamma stimulation, and hybridized with a rat LMP2 cDNA probe by mRNA expression was assessed by Northern hybridization. IFNgamma strongly induced LMP2 expression, beginning at 12 hours post-stimulation and plateauing at 48 hours. No oncocytic changes were seen morphologically in the thyroid cells during these culture time points.
###end p 79
###begin p 80
(1.75 MB TIF)
###end p 80
###begin p 81
Click here for additional data file.
###end p 81
###begin p 82
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 233 248 <span type="species:ncbi:10090">transgenic mice</span>
(A) Thyroidal morphology of mice lacking just LMP2: the thyroid architecture is preserved (left panel), but thyrocytes are flatter (right panel) than wild type thyrocytes (right panel, inset). (B) Thyroid morphology of thyr-IFNgamma transgenic mice lacking LMP7: the absence of LMP7 has no effect on the oncocytic phenotype induced by IFNgamma.
###end p 82
###begin p 83
(9.59 MB TIF)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin p 85
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 156 160 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 260 264 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 291 295 279 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 132 147 <span type="species:ncbi:10090">transgenic mice</span>
###xml 170 185 <span type="species:ncbi:10090">transgenic mice</span>
###xml 330 334 <span type="species:ncbi:10090">mice</span>
Radioactive iodine accumulation in thyroid. The radioactive iodine accumulation is decreased in mice lacking LMP2, in thyr-IFNgamma transgenic mice, and in thyr-IFNgamma transgenic mice lacking LMP2. No significant difference was observed among LMP2 knockout, thyr-IFNgamma transgenics, and thyr-IFNgamma transgenic/LMP2 knockout mice.
###end p 85
###begin p 86
(0.27 MB TIF)
###end p 86
###begin p 87
Click here for additional data file.
###end p 87
###begin p 88
###xml 25 30 <span type="species:ncbi:9606">human</span>
Histological analysis of human Hurthle cells. (A) LMP2 expression varies in different areas of Hurthle cell adenomas: expression is lower (left panel, inset) in areas with more complex histopathology (left panel) than in areas with a more uniform appearance (right panel). (B) LMP7 expression in Hashimoto thyroiditis (left panel), Hurthle cell adenoma (middle panel), and Hurthle cell carcinoma (right panel).
###end p 88
###begin p 89
(3.13 MB TIF)
###end p 89
###begin p 90
Click here for additional data file.
###end p 90
###begin p 91
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
Top 10 genes expressed in thyr-IFNgamma transgenic mouse thyrocytes (total tag # is 43,718).
###end p 91
###begin p 92
(0.06 MB DOC)
###end p 92
###begin p 93
Click here for additional data file.
###end p 93
###begin p 94
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thyr</italic>
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
Top 10 genes expressed only in thyr-IFNgamma transgenic mouse thyrocytes.
###end p 94
###begin p 95
(0.04 MB DOC)
###end p 95
###begin p 96
Click here for additional data file.
###end p 96
###begin p 97
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
Top 10 genes expressed in wild-type mouse thyrocytes (total tag # is 43,908).
###end p 97
###begin p 98
(0.05 MB DOC)
###end p 98
###begin p 99
Click here for additional data file.
###end p 99
###begin p 100
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
Top 10 genes expressed only in wild-type mouse thyrocytes.
###end p 100
###begin p 101
(0.03 MB DOC)
###end p 101
###begin p 102
Click here for additional data file.
###end p 102
###begin title 103
References
###end title 103
###begin article-title 104
The epidemiology of autoimmune diseases.
###end article-title 104
###begin article-title 105
Karl Hurthle! Now, who was he?
###end article-title 105
###begin article-title 106
Oncocytic neoplasms of the thyroid gland.
###end article-title 106
###begin article-title 107
The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review.
###end article-title 107
###begin article-title 108
###xml 18 33 <span type="species:ncbi:10090">transgenic mice</span>
Hypothyroidism in transgenic mice expressing IFN-gamma in the thyroid.
###end article-title 108
###begin article-title 109
Increased thyroidal fat and goitrous hypothyroidism induced by interferon-gamma.
###end article-title 109
###begin article-title 110
The proteasome: overview of structure and functions.
###end article-title 110
###begin article-title 111
Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII.
###end article-title 111
###begin article-title 112
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
###end article-title 112
###begin article-title 113
###xml 107 115 <span type="species:ncbi:9606">patients</span>
LMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis.
###end article-title 113
###begin article-title 114
###xml 53 58 <span type="species:ncbi:9606">human</span>
Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo.
###end article-title 114
###begin article-title 115
Strong associations of psoriasis with antigen processing LMP and transport genes TAP differ by gender and phenotype.
###end article-title 115
###begin article-title 116
Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases.
###end article-title 116
###begin article-title 117
Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i).
###end article-title 117
###begin article-title 118
Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjogren's syndrome.
###end article-title 118
###begin article-title 119
Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders.
###end article-title 119
###begin article-title 120
###xml 4 8 <span type="species:ncbi:10090">mice</span>
NOD mice are defective in proteasome production and activation of NF-kappaB.
###end article-title 120
###begin article-title 121
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Reply to 'LMP2 expression and proteasome activity in NOD mice'.
###end article-title 121
###begin article-title 122
###xml 47 51 <span type="species:ncbi:10090">mice</span>
LMP2 expression and proteasome activity in NOD mice.
###end article-title 122
###begin article-title 123
###xml 47 51 <span type="species:ncbi:10090">mice</span>
LMP2 expression and proteasome activity in NOD mice.
###end article-title 123
###begin article-title 124
Proteasome subunits, low-molecular-mass polypeptides 2 and 7 are hyperexpressed by target cells in autoimmune thyroid disease but not in insulin-dependent diabetes mellitus: implications for autoimmunity.
###end article-title 124
###begin article-title 125
Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits.
###end article-title 125
###begin article-title 126
The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome.
###end article-title 126
###begin article-title 127
Development of the proteasome inhibitor PS-341.
###end article-title 127
###begin article-title 128
Bortezomib: proteasome inhibition as an effective anticancer therapy.
###end article-title 128
###begin article-title 129
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
###end article-title 129
###begin article-title 130
###xml 71 75 <span type="species:ncbi:10090">mice</span>
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
###end article-title 130
###begin article-title 131
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
###end article-title 131
###begin article-title 132
The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites.
###end article-title 132
###begin article-title 133
###xml 17 43 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.
###end article-title 133
###begin article-title 134
###xml 146 150 <span type="species:ncbi:10090">mice</span>
Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.
###end article-title 134
###begin article-title 135
Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia.
###end article-title 135
###begin article-title 136
Targeting proteasome worsens atherosclerosis.
###end article-title 136
###begin article-title 137
Chronic proteasome inhibition contributes to coronary atherosclerosis.
###end article-title 137
###begin article-title 138
Targeting of the proteasome worsens atherosclerosis?
###end article-title 138
###begin article-title 139
Update on thyroid cancer.
###end article-title 139
###begin article-title 140
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 78 112 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
Immunoproteasome-deficient mice mount largely normal CD8+ T cell responses to lymphocytic choriomeningitis virus infection and DNA vaccination.
###end article-title 140
###begin article-title 141
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.
###end article-title 141
###begin article-title 142
Using the transcriptome to annotate the genome.
###end article-title 142
###begin p 143
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 143
###begin p 144
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by National Institutes of Health (NIH) grants DK55670 and DK080334 to PC, and by an American Thyroid Association Grant () to HJK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 144

